Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nordion
Sales of the lymphoma drug Monjuvi continue to underwhelm but MorphoSys believes that its investigational BET inhibitor, pelabresib, can become a standard of care for the rare bone marrow disease myelofibrosis.
Plus deals involving Santen/Harrow/Visiox, Aurobindo/BioFactura, AFT/Crossject, Imugene/RenovoRx, Biotheus/BioNTech, GeneQuantum/InxMed, ObsEva/Yuyuan, Monopar/National University of Singapore and Doer Biologics/BioNTech.
Deal brings Lilly a Phase II activin receptor-targeting antibody that could provide another tool in battling obesity. This is Lilly’s fourth M&A transaction since 20 June.
Urmi Prasad Richardson brings a wealth of science and business experience to diagnostics and life sciences multinational Thermo Fisher Scientific, where for the past two years she has been president of the group’s vast and varied EMEA business. The Indian-born, Germany-based executive has surmounted a range of challenges along the way and offers her story as inspiration for others.
- Medical Devices
- Other Names / Subsidiaries
- MDS Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.